TYKDEUVY
Live / Applied — Fourth extension granted (statement of use) (as of 28 May 2025)
What this means for you
Not registered yet, but its 22 Feb 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97278224
- Mark type
- Stylized text
- Filed
- 22 Feb 2022
- Published for opposition
- 11 Apr 2023
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 12 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 May 2025 — SOU EXTENSION 4 GRANTED
- 28 May 2025 — SOU EXTENSION 4 FILED
- 28 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Nov 2024 — SOU EXTENSION 3 GRANTED
- 25 Nov 2024 — SOU EXTENSION 3 FILED
- 25 Nov 2024 — SOU TEAS EXTENSION RECEIVED
- 21 May 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 May 2024 — SOU EXTENSION 2 GRANTED
- 20 May 2024 — SOU EXTENSION 2 FILED
- 20 May 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Nov 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2023 — SOU EXTENSION 1 GRANTED